Key Points
- EVP Scott Dreyer sold 49,976 shares of Collegium on March 3 at an average of $40.41 for about $2.02M, cutting his ownership by 41.05% to 71,770 shares; the transaction was disclosed in an SEC filing.
- Collegium recently missed quarterly estimates (EPS $2.04 vs. est. $2.20 and revenue slightly below expectations), but analysts still rate the stock a "Moderate Buy" with an average target of about $53.
Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) EVP Scott Dreyer sold 49,976 shares of the company's stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $40.41, for a total transaction of $2,019,530.16. Following the completion of the sale, the executive vice president directly owned 71,770 shares of the company's stock, valued at $2,900,225.70. The trade was a 41.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Scott Dreyer also recently made the following trade(s):
- On Monday, December 8th, Scott Dreyer sold 17,600 shares of Collegium Pharmaceutical stock. The shares were sold at an average price of $48.17, for a total value of $847,792.00.
Collegium Pharmaceutical Stock Performance
Shares of COLL stock traded down $0.38 during midday trading on Friday, hitting $36.90. The company had a trading volume of 102,826 shares, compared to its average volume of 444,218. The stock has a market cap of $1.17 billion, a price-to-earnings ratio of 21.58 and a beta of 0.67. The company has a debt-to-equity ratio of 2.59, a current ratio of 1.57 and a quick ratio of 1.48. The company's 50 day simple moving average is $45.74 and its 200 day simple moving average is $42.09. Collegium Pharmaceutical, Inc. has a 52-week low of $23.23 and a 52-week high of $50.79.
Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last posted its quarterly earnings data on Thursday, February 26th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, missing analysts' consensus estimates of $2.20 by ($0.16). The firm had revenue of $205.45 million during the quarter, compared to analysts' expectations of $206.36 million. Collegium Pharmaceutical had a net margin of 8.05% and a return on equity of 98.65%. The business's quarterly revenue was up 12.9% on a year-over-year basis. During the same quarter last year, the business earned $1.77 earnings per share. Research analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several research firms have issued reports on COLL. Weiss Ratings reiterated a "buy (b-)" rating on shares of Collegium Pharmaceutical in a research report on Monday, December 29th. Truist Financial set a $58.00 price objective on Collegium Pharmaceutical in a research report on Tuesday, February 10th. Barclays reduced their target price on Collegium Pharmaceutical from $58.00 to $56.00 and set an "overweight" rating for the company in a report on Friday, January 9th. Needham & Company LLC lowered their price target on shares of Collegium Pharmaceutical from $56.00 to $54.00 and set a "buy" rating on the stock in a research note on Thursday, February 26th. Finally, Zacks Research lowered shares of Collegium Pharmaceutical from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, January 6th. Five investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, Collegium Pharmaceutical presently has an average rating of "Moderate Buy" and an average target price of $53.00.
View Our Latest Analysis on Collegium Pharmaceutical
Hedge Funds Weigh In On Collegium Pharmaceutical
Hedge funds have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp lifted its stake in Collegium Pharmaceutical by 3.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 249,875 shares of the specialty pharmaceutical company's stock valued at $7,389,000 after buying an additional 7,614 shares in the last quarter. Assenagon Asset Management S.A. raised its stake in Collegium Pharmaceutical by 90.5% in the 3rd quarter. Assenagon Asset Management S.A. now owns 195,589 shares of the specialty pharmaceutical company's stock valued at $6,844,000 after purchasing an additional 92,898 shares during the last quarter. Ballast Asset Management LP raised its stake in Collegium Pharmaceutical by 31.1% in the 3rd quarter. Ballast Asset Management LP now owns 114,315 shares of the specialty pharmaceutical company's stock valued at $4,000,000 after purchasing an additional 27,109 shares during the last quarter. Versor Investments LP purchased a new position in Collegium Pharmaceutical in the 3rd quarter valued at about $1,337,000. Finally, Eastern Bank boosted its stake in shares of Collegium Pharmaceutical by 487.5% during the 3rd quarter. Eastern Bank now owns 54,843 shares of the specialty pharmaceutical company's stock worth $1,919,000 after purchasing an additional 45,508 shares during the last quarter.
Collegium Pharmaceutical Company Profile
(
Get Free Report)
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company's core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.
The company's principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
